Recombinant Anser caerulescens NADH-ubiquinone oxidoreductase chain 5 (MT-ND5)

What is MT-ND5 and what role does it play in mitochondrial function?

The evolutionary conservation of specific regions within MT-ND5 indicates their functional importance. The carboxyterminal end of the subunit is notably less conserved compared to other regions, suggesting potentially different functional constraints across species . Interestingly, certain haplogroups (particularly haplogroup J) show evidence of lineage-specific selection in the MT-ND5 gene, with fewer segregating sites and nonsynonymous mutations than expected within nucleotide positions 12478-13611, suggesting stronger selective pressure on this region in specific human lineages .

How is recombinant Anser caerulescens MT-ND5 protein typically prepared for research use?

Recombinant Anser caerulescens MT-ND5 protein is typically expressed in E. coli expression systems with an N-terminal His-tag to facilitate purification . The full-length protein (covering amino acids 1-214) is produced through recombinant DNA technology, where the coding sequence is inserted into an appropriate expression vector, transformed into E. coli, and then induced for protein expression . After expression, the protein undergoes purification, typically through affinity chromatography exploiting the His-tag, followed by additional purification steps to achieve a final purity greater than 90% as determined by SDS-PAGE .

The purified protein is typically lyophilized to ensure stability during storage and transportation . For research applications, proper reconstitution is essential—the manufacturer recommends reconstituting the lyophilized protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL . To enhance stability during long-term storage, addition of glycerol to a final concentration of 5-50% is recommended, with subsequent aliquoting and storage at -20°C or -80°C to prevent repeated freeze-thaw cycles that could compromise protein integrity . Proper reconstitution and storage conditions are critical for maintaining the structural and functional characteristics of the recombinant protein for experimental use.

What are the optimal storage and handling conditions for recombinant MT-ND5 protein?

The optimal storage and handling conditions for recombinant MT-ND5 protein are critical for maintaining its structural integrity and biological activity. The protein is supplied as a lyophilized powder in a Tris/PBS-based buffer containing 6% trehalose at pH 8.0 . For long-term storage, it is recommended to store the unopened vial at -20°C or -80°C upon receipt . Before opening the vial, it should be briefly centrifuged to ensure all content is at the bottom, preventing loss of material when opening .

For reconstitution, deionized sterile water should be used to achieve a concentration of 0.1-1.0 mg/mL . Working aliquots for frequent use can be stored at 4°C for up to one week, but for longer periods, the addition of glycerol (typically to a final concentration of 50%) as a cryoprotectant is recommended before aliquoting and storing at -20°C or -80°C . It is particularly important to avoid repeated freeze-thaw cycles as these can significantly reduce protein activity and stability . For experiments requiring precise concentration determination, standard protein quantification methods such as Bradford or BCA assays may be employed after reconstitution to confirm protein concentration before experimental use.

How can recombinant MT-ND5 be used to study mitochondrial complex I assembly and function?

Advanced biophysical techniques such as cryo-electron microscopy can be combined with recombinant MT-ND5 to elucidate structural details of complex I components and their interactions. Additionally, reconstituted proteoliposomes containing recombinant MT-ND5 and other complex I subunits can be used to measure proton pumping efficiency and electron transfer rates, providing insights into the functional aspects of the complex. Such studies are particularly valuable for understanding the molecular mechanisms underlying mitochondrial disorders associated with MT-ND5 mutations, as the recombinant protein allows for controlled experimental conditions that are difficult to achieve when studying native mitochondrial complexes in cellular systems with variable genetic backgrounds.

What experimental approaches can be used to study the effects of MT-ND5 pathogenic variants?

Several sophisticated experimental approaches can be employed to investigate the effects of MT-ND5 pathogenic variants on mitochondrial function and disease pathogenesis. One primary approach involves site-directed mutagenesis of recombinant MT-ND5 to introduce specific pathogenic variants such as m.13513G>A or m.13094T>C, followed by functional assays to assess their impact on protein structure, complex I assembly, and enzyme activity . These recombinant proteins can be incorporated into liposomes or nanodiscs to study their effects on proton pumping and electron transfer in a controlled environment.

Cellular models offer another powerful approach, where patient-derived cells or genetically modified cell lines expressing MT-ND5 variants can be analyzed for complex I activity, ATP production, reactive oxygen species generation, and mitochondrial membrane potential. Advanced techniques such as seahorse respirometry can quantify the bioenergetic consequences of these variants . For tissue-specific effects, researchers can employ histological and ultrastructural analyses similar to those described in case reports, where abnormal mitochondrial morphology was observed in kidney tissues of patients with the m.13513G>A variant . Electron microscopy revealed distinctive mitochondrial alterations, including cyst-like structures in podocytes and various abnormalities in proximal tubules such as myelin figures, long narrowed mitochondria, and electron-dense inclusions .

Animal models expressing MT-ND5 variants provide insights into the systemic manifestations of these mutations. Additionally, heteroplasmy analysis across different tissues can reveal correlations between mutant load and phenotypic severity, as demonstrated in cases where variable loads of the m.13513G>A mutant mtDNA were found in blood, urinary sediment, and kidney biopsies . These multifaceted approaches collectively contribute to our understanding of how MT-ND5 variants lead to diverse clinical phenotypes.

How does MT-ND5 research contribute to understanding mitochondrial disease heterogeneity?

MT-ND5 research provides crucial insights into the heterogeneity of mitochondrial diseases by elucidating the complex relationship between genotype and phenotype. The m.13513G>A pathogenic variant in MT-ND5, for instance, has been associated with remarkably diverse clinical manifestations including Leber Hereditary Optic Neuropathy (LHON), MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes), Leigh syndrome, Wolff-Parkinson-White syndrome, nephropathy, sensorineural deafness, and subcortical and cerebellar atrophy . This extraordinary clinical variability from a single mutation demonstrates how alterations in the same gene can affect multiple organ systems differently.

Research has revealed that heteroplasmy—the variable proportion of mutant mtDNA in different tissues—significantly contributes to this phenotypic heterogeneity . Studies have shown good correlation between heteroplasmic mutant load and disease severity, with tissue-specific thresholds determining clinical manifestations . This explains why some patients with MT-ND5 mutations present primarily with neurological symptoms while others display predominant renal or cardiac involvement. Additionally, investigation of MT-ND5 variants has highlighted the importance of nuclear-mitochondrial interactions in disease expression, as the same mitochondrial mutation can present differently depending on the nuclear genetic background .

The discovery that certain MT-ND5 disorders can be misdiagnosed as other conditions, such as seronegative neuromyelitis optica spectrum disorder (NMOSD), emphasizes the importance of comprehensive biochemical and genetic testing in diagnosis . This research has fundamentally changed our approach to mitochondrial disease diagnosis, moving from symptom-based to molecular-based classification, and has revealed unexpected connections between seemingly unrelated clinical entities, broadening our understanding of mitochondrial pathophysiology.

What is the spectrum of clinical manifestations associated with MT-ND5 mutations?

MT-ND5 mutations are associated with a remarkably broad spectrum of clinical manifestations, demonstrating the critical role of complex I in multiple tissue types. The m.13513G>A pathogenic variant alone has been identified in over 40 individuals with heterogeneous clinical presentations . These include Leber Hereditary Optic Neuropathy (LHON), characterized by subacute loss of central vision due to retinal ganglion cell degeneration; Leigh syndrome (LS), a severe neurometabolic disorder with bilateral basal ganglia lesions; MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes); and Wolff-Parkinson-White (WPW) syndrome, a cardiac conduction abnormality .

More recently, the clinical spectrum has expanded to include mitochondrial nephropathy with focal segmental glomerulosclerosis (FSGS), as evidenced by case reports showing patients with kidney biopsies revealing glomerular and tubular cell involvement and abnormal mitochondrial ultrastructure . These patients often present with chronic kidney disease preceding neurological manifestations. Additionally, sensorineural hearing loss, subcortical and cerebellar atrophy have been documented . Brain MRI findings in affected individuals may include ventricular dilation, periventricular hyperintensities, and bilateral symmetrical signal changes in the globi pallidi consistent with mineralization .

The variable tissue involvement reflects the ubiquitous requirement for mitochondrial energy production, with particularly high demand in metabolically active tissues such as neural retina, central nervous system, kidneys, and cardiac muscle. This expansive phenotypic spectrum challenges clinicians to consider MT-ND5-related disorders in the differential diagnosis of various neurological, renal, and multi-system conditions.

How can researchers differentiate between pathogenic MT-ND5 variants and benign polymorphisms?

Differentiating between pathogenic MT-ND5 variants and benign polymorphisms requires a multifaceted approach combining evolutionary, biochemical, and clinical data. Researchers typically begin by assessing evolutionary conservation of the affected amino acid residue, as mutations in highly conserved regions are more likely to be deleterious. For instance, the m.13513G>A variant leads to substitution of an evolutionarily conserved amino acid (D393N) in the ND5 subunit, suggesting functional importance . Comparative analysis across species and examination of conservation scores help gauge the potential impact of specific variants.

Biochemical functional studies provide crucial evidence of pathogenicity. Researchers can measure complex I activity, oxygen consumption rates, ATP production, and reactive oxygen species generation in patient-derived cells or recombinant systems expressing the variant. A demonstrable defect in oxidative phosphorylation supports pathogenicity . Heteroplasmy analysis also yields valuable insights, as a correlation between mutant load and biochemical or clinical severity strongly suggests pathogenicity . In contrast, benign polymorphisms typically show no such correlation.

Population frequency data from mitochondrial databases help distinguish rare pathogenic variants from common polymorphisms. The presence of the same variant in multiple unrelated patients with similar phenotypes strengthens the case for pathogenicity, while frequent occurrence in healthy individuals suggests a benign nature. Haplogroup-specific analyses are particularly important, as some variants may be pathogenic only in certain mitochondrial backgrounds . For example, the unique pattern of selection in the MT-ND5 gene in haplogroup J suggests different functional constraints than in other lineages . Finally, family segregation studies and analysis of maternal transmission patterns can provide additional evidence for distinguishing pathogenic variants from neutral polymorphisms.

What diagnostic challenges exist in identifying MT-ND5-related disorders?

Diagnosing MT-ND5-related disorders presents several significant challenges that researchers and clinicians must navigate. First, the remarkable phenotypic heterogeneity associated with MT-ND5 mutations means that patients may present with predominantly neurological, renal, cardiac, or multi-system involvement, making clinical recognition difficult . This heterogeneity can lead to misdiagnosis or delayed diagnosis, as illustrated by cases initially diagnosed with seronegative neuromyelitis optica spectrum disorder (NMOSD) that were later confirmed to have MT-ND5-related mitochondrial disorders .

A second major challenge involves the tissue-specific expression and variable heteroplasmy levels across different tissues. The m.13513G>A pathogenic variant, for example, may show remarkably low heteroplasmic load in blood cells compared to affected tissues like kidney or nervous system . This variability necessitates obtaining tissue samples from clinically affected organs for accurate molecular diagnosis, which can be invasive and not always feasible. In the reported case with nephropathy, the heteroplasmic mutation load was much higher in kidney tissue than in blood, highlighting the limitation of blood-based testing alone .

Technical challenges in mitochondrial DNA sequencing and heteroplasmy detection also exist. Low-level heteroplasmy may be missed by conventional sequencing methods, requiring more sensitive techniques like next-generation sequencing. Additionally, distinguishing pathogenic MT-ND5 variants from the numerous polymorphisms in the mitochondrial genome requires careful interpretation of sequence data and correlation with clinical, biochemical, and histological findings . The maternal inheritance pattern of mtDNA can further complicate diagnosis, as de novo mutations or variable expression in maternal relatives may obscure the genetic etiology. These challenges collectively underscore the importance of a multidisciplinary approach combining clinical evaluation, tissue-specific studies, and advanced genetic analysis for accurate diagnosis of MT-ND5-related disorders.

What techniques are most effective for measuring the functional impact of MT-ND5 mutations?

Assessing the functional impact of MT-ND5 mutations requires a comprehensive toolbox of biochemical, cellular, and molecular techniques. Spectrophotometric enzyme assays measuring NADH:ubiquinone oxidoreductase (complex I) activity provide direct quantification of the enzymatic consequences of MT-ND5 mutations. These assays can be performed on isolated mitochondria, tissue homogenates, or cultured cells to determine the degree of complex I deficiency . Blue Native-PAGE followed by in-gel activity staining offers complementary information about complex I assembly and stability in the presence of mutations.

High-resolution respirometry using platforms such as Seahorse XF analyzers or Oroboros Oxygraph enables detailed assessment of cellular bioenergetics by measuring oxygen consumption rates under different conditions, including basal respiration, ATP-linked respiration, proton leak, and maximal respiratory capacity . These parameters provide insights into how MT-ND5 mutations affect integrated mitochondrial function in intact cells. Membrane potential measurements using potentiometric dyes like TMRM (tetramethylrhodamine methyl ester) can reveal defects in proton pumping resulting from MT-ND5 mutations.

For assessing tissue-specific effects, histochemical and immunohistochemical techniques are valuable. The combined cytochrome c oxidase (COX) and succinate dehydrogenase (SDH) histochemical stain can identify cells with mitochondrial dysfunction, while immunohistochemistry for complex I subunits can reveal assembly defects . Electron microscopy provides ultrastructural information, as demonstrated in cases where abnormal mitochondrial morphology was observed in kidney tissues of patients with the m.13513G>A variant . For molecular analysis, next-generation sequencing with high depth of coverage allows accurate quantification of heteroplasmy levels across tissues, which is crucial for establishing genotype-phenotype correlations in MT-ND5-related disorders .

How can researchers optimize heterologous expression systems for MT-ND5 functional studies?

Optimizing heterologous expression systems for MT-ND5 functional studies requires careful consideration of several key factors due to the protein's hydrophobic nature and mitochondrial origin. Selecting the appropriate expression system is critical: while E. coli is commonly used for producing recombinant MT-ND5 protein as demonstrated in the available commercial preparation , eukaryotic systems like yeast, insect cells, or mammalian cells may provide a more native-like environment for proper folding and post-translational modifications. For E. coli expression, using specialized strains designed for membrane protein expression (such as C41(DE3) or C43(DE3)) can improve yields of functional protein.

The construct design significantly impacts expression efficiency and protein functionality. Including affinity tags (like the His-tag used in the commercial preparation) facilitates purification, but their position must be carefully chosen to minimize interference with protein folding or function . For hydrophobic proteins like MT-ND5, adding solubility-enhancing tags such as SUMO or MBP may improve expression and folding. Codon optimization for the host organism is particularly important for mitochondrial genes due to differences in codon usage between mitochondrial and nuclear genomes.

Expression conditions require careful optimization. Lower induction temperatures (16-25°C rather than 37°C) often improve the folding of membrane proteins. For purification and functional studies, selecting appropriate detergents is crucial—mild detergents like DDM (n-dodecyl β-D-maltoside) or digitonin often preserve membrane protein structure and function better than harsher detergents. Reconstitution into liposomes or nanodiscs provides a more native-like lipid environment for functional studies. Finally, implementing quality control measures like circular dichroism spectroscopy to assess secondary structure, or binding assays to verify interaction with known complex I partners, ensures that the expressed MT-ND5 retains its natural properties and is suitable for downstream functional analyses.

What are the best approaches for studying MT-ND5 variants in animal models?

Developing effective animal models for studying MT-ND5 variants presents unique challenges due to the mitochondrial location of the gene and the phenomenon of heteroplasmy. Several complementary approaches have proven valuable for investigating these complex genetic conditions. The creation of transmitochondrial cytoplasmic hybrid (cybrid) cell lines, while not animal models per se, represents an important initial step where patient-derived mitochondria containing MT-ND5 mutations are transferred to a cell line lacking mtDNA (ρ0 cells), allowing the study of mitochondrial function against a uniform nuclear background . These cybrids can subsequently be used to generate heteroplasmic mitochondrial mice through cybrid transfer into mouse embryonic stem cells.

For direct animal modeling, the mitochondrial mutator mouse approach utilizes mice expressing a proofreading-deficient version of mtDNA polymerase gamma (POLG), generating random mtDNA mutations including in MT-ND5. While this doesn't target specific variants, it allows for studying the general impact of mitochondrial mutations. More targeted approaches include bacterial artificial chromosome (BAC) transgenic mice expressing the entire human mitochondrial genome with specific MT-ND5 mutations, though integration occurs in the nuclear genome rather than mitochondria.

Newer techniques utilizing mitochondrially targeted nucleases (mitoTALENs or mitoCRISPRs) allow for selective elimination of specific mtDNA sequences in mouse models, potentially enabling the creation of animals with controlled heteroplasmy levels of MT-ND5 mutations. Regardless of the approach, comprehensive phenotyping is essential, including behavioral assessments for neurological manifestations, renal function tests for nephropathy, cardiac evaluations, and histopathological analyses with special attention to mitochondrial ultrastructure in various tissues—similar to the analysis performed in human kidney biopsies that revealed distinctive mitochondrial abnormalities in patients with the m.13513G>A variant . These animal models provide invaluable insights into the tissue-specific effects of MT-ND5 mutations and serve as platforms for testing potential therapeutic interventions.

How might advances in structural biology enhance our understanding of MT-ND5 function?

Recent breakthroughs in cryo-electron microscopy and other structural biology techniques promise to revolutionize our understanding of MT-ND5's role in complex I architecture and function. As a hydrophobic polypeptide with multiple transmembrane helices and a large conserved domain between helices IX and XII, MT-ND5 forms a critical part of the membrane-spanning domain of complex I . Advanced structural studies can reveal the precise orientation of these helices and the molecular interactions between MT-ND5 and neighboring subunits that enable proton translocation. High-resolution structures may also identify water channels or other structural features essential for understanding the mechanism of energy conversion.

Comparative structural analysis between wild-type MT-ND5 and pathogenic variants, such as those containing the m.13513G>A mutation, could reveal how specific amino acid substitutions (like D393N) disrupt protein folding, complex I assembly, or function . Such structural insights would explain how seemingly small changes in protein sequence lead to profound functional consequences and diverse clinical manifestations. Additionally, structural studies across species and haplogroups may clarify why certain regions of MT-ND5 show evidence of lineage-specific selection, particularly in human haplogroup J .

The integration of structural data with molecular dynamics simulations will further enhance our understanding of MT-ND5's role in proton pumping and energy transduction. These computational approaches can model conformational changes during the catalytic cycle and predict how pathogenic variants alter these dynamics. Such detailed structural and dynamic information will not only advance our fundamental understanding of mitochondrial bioenergetics but also inform rational design of therapeutic interventions targeting specific structural or functional domains of MT-ND5 affected in mitochondrial disorders.

What potential therapeutic strategies are emerging for MT-ND5-related disorders?

Emerging therapeutic strategies for MT-ND5-related disorders reflect our growing understanding of mitochondrial disease pathophysiology and advances in genetic medicine. One promising approach involves shifting heteroplasmy ratios to reduce the burden of mutant mtDNA. Mitochondrially targeted nucleases, including mitoTALENs and mitoCRISPRs, can selectively cleave mutant mtDNA molecules while sparing wild-type ones, potentially reducing heteroplasmy below the threshold for disease expression . These approaches show particular promise for MT-ND5 disorders where clinical severity correlates strongly with mutant load.

Metabolic bypass strategies aim to circumvent defective complex I by enhancing electron flow through alternative pathways. Succinate, which donates electrons directly to complex II, or compounds that facilitate direct transfer from NADH to CoQ10 (such as idebenone) may benefit patients with MT-ND5 mutations . These approaches are particularly relevant given that the m.13513G>A variant leads to impaired oxidative phosphorylation due to dysfunction of the ND5 subunit of complex I .

Mitochondrial augmentation therapy, where healthy mitochondria are transferred into affected cells, represents another innovative approach currently under investigation. For kidney manifestations of MT-ND5 disorders, such as the focal segmental glomerulosclerosis observed in patients with the m.13513G>A variant, targeted renal therapies combining conventional nephroprotective agents with mitochondrial-targeted antioxidants may slow disease progression . Gene therapy approaches, including allotopic expression of recoded MT-ND5 from the nuclear genome, are also under exploration, although the challenges of importing hydrophobic proteins like MT-ND5 into mitochondria remain significant.

These diverse therapeutic strategies, while still largely experimental, offer hope for patients with MT-ND5-related disorders that currently lack effective treatments. As our understanding of the structure-function relationships in MT-ND5 advances, more targeted therapeutic interventions will likely emerge.

How can systems biology approaches integrate MT-ND5 research into broader mitochondrial disease frameworks?

Systems biology approaches offer powerful frameworks for integrating MT-ND5 research into comprehensive models of mitochondrial disease pathophysiology. These holistic approaches combine multi-omics data (genomics, transcriptomics, proteomics, metabolomics) to create network-based models that capture the complex interactions between MT-ND5 variants and broader cellular processes. By analyzing how MT-ND5 mutations affect not only complex I function but also ripple through interconnected metabolic pathways, systems biology can explain the diverse tissue-specific manifestations observed in patients .

Network medicine approaches can identify how MT-ND5 dysfunction affects seemingly unrelated biological processes, potentially explaining the diverse phenotypes ranging from optic atrophy to nephropathy . These methods can also reveal compensatory mechanisms that may explain why some tissues are affected while others are spared in patients with the same MT-ND5 mutation. Furthermore, computational models can predict how heteroplasmy thresholds differ across tissues based on their energetic demands and reliance on oxidative phosphorylation.

Patient stratification through machine learning analysis of multi-omics data may identify molecular signatures that predict which patients with MT-ND5 mutations will develop specific manifestations like LHON, nephropathy, or neurological disorders . This precision medicine approach could guide personalized preventive strategies before symptoms appear. Additionally, systems pharmacology can identify existing drugs that might be repurposed for MT-ND5-related disorders by targeting relevant nodes in the affected networks. By placing MT-ND5 research within this broader systems context, researchers can develop more comprehensive models of mitochondrial disease mechanisms, identify novel biomarkers for disease progression, and design more effective therapeutic interventions that address the complex downstream consequences of MT-ND5 dysfunction rather than just the primary defect.